Gastroenteritis

Gastroenterology
5
Pipeline Programs
5
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
2
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 6 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
1
Bacillus ClausiiPhase 31 trial
Active Trials
NCT00457353Completed264
HilleVax
HilleVaxMA - Boston
3 programs
1
2
HIL-214Phase 2/31 trial
HIL-214Phase 2/31 trial
HIL-214Phase 21 trial
Active Trials
NCT05972733CompletedEst. Nov 2023
NCT05836012CompletedEst. Jul 2024
NCT05281094TerminatedEst. Sep 2024
Takeda
TakedaTOKYO, Japan
1 program
1
NoV GI.1/GII.4 Bivalent VLP VaccinePhase 1Vaccine1 trial
Active Trials
NCT01168401Completed102Est. Jan 2013
Abbott
AbbottABBOTT PARK, IL
1 program
5% dextrose in normal salineN/A1 trial
Active Trials
NCT01343758Completed188Est. Jul 2011
M&
Merck & Co.RAHWAY, NJ
1 program
Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in KoreaN/A1 trial
Active Trials
NCT00669929Unknown200Est. Jun 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiBacillus Clausii
HilleVaxHIL-214
HilleVaxHIL-214
HilleVaxHIL-214
TakedaNoV GI.1/GII.4 Bivalent VLP Vaccine
Merck & Co.Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea
Abbott5% dextrose in normal saline

Clinical Trials (7)

Total enrollment: 754 patients across 7 trials

NCT00457353SanofiBacillus Clausii

ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children

Start: Mar 2007264 patients
Phase 3Completed
NCT05836012HilleVaxHIL-214

Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

Start: Jun 2023Est. completion: Jul 2024
Phase 2/3Completed
NCT05281094HilleVaxHIL-214

Efficacy and Safety of Two Doses of HIL-214 in Children

Start: Apr 2022Est. completion: Sep 2024
Phase 2/3Terminated
NCT05972733HilleVaxHIL-214

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

Start: Aug 2023Est. completion: Nov 2023
Phase 2Completed
NCT01168401TakedaNoV GI.1/GII.4 Bivalent VLP Vaccine

Bivalent Norovirus Vaccine Study

Start: Sep 2010Est. completion: Jan 2013102 patients
Phase 1Completed
NCT00669929Merck & Co.Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea

Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea

Start: May 2008Est. completion: Jun 2009200 patients
N/AUnknown
NCT01343758Abbott5% dextrose in normal saline

Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children

Start: Jan 2007Est. completion: Jul 2011188 patients
N/ACompleted

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
6h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)